Highlights NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq Other stock markets 20:59:56 28/06/2024 BST			5-day change	1st Jan Change
1.12 ^USD	+9.80%		+24.72%	+42.68%

06-24	Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...
06-24	NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	06-24	CI
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq	06-21	MT
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	05-07	CI
NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	04-22	MT
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	04-22	CI
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	04-18	CI
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics	04-09	CI
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial	02-21	CI
NeuroSense Gets Non-Compliance Notice From Nasdaq	12-28	MT
Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial	12-14	CI
NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints	12-05	CI
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-28	CI
Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness	11-13	CI
NeuroSense Therapeutics Ltd. Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023	11-06	CI
Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis	04/10/23	CI
Neurosense Therapeucs Ltd. Opens an Eu Office	20/09/23	CI
European Medicines Agency Grants Neurosense SME Status	20/09/23	CI
NeuroSense Secures Patents in Europe, Japan, Israel for ALS Drug Candidate; Shares Rise	19/09/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Highlights

Filters